thunderbird, to rephrase abobo the answer is no. Biota do not receive anything from the options GSK sells.
I'm not sure why everyone is so focused on Relenza patent expiration which is not until 2013. Investors have four years to worry about that. http://www.gsk.com/financial/reports/ar/report/descrip_of_bus/intell_property/intell_prop.html